N/A
N=78
Salivary and Serum Leptin Levels in Oral Lichen Planus Patients: A Case-control Study.
Oral Lichen Planus · Leptin Levels
Bottom Line
View on ClinicalTrials.gov: NCT06078579 ↗Enrolled (actual)
78
Serious AEs
0.0%
Results posted
Mar 2025
Primary outcome: Primary: Serum Leptin Level — 13.23; 4.20 ng/ml
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Leptin (Diagnostic_test)
- Age
- Adult, Older Adult · 30+ yrs
- Sex
- All
- Sponsor
- Cairo University
- Primary completion
- Nov 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Serum Leptin Level |
13.23; 4.20 | — |
| SECONDARY Salivary Leptin Levels |
15.31; 4.90 | — |
Summary
This study aims to evaluate the levels of leptin in both saliva and serum samples of patients diagnosed with oral lichen.
Eligibility Criteria
Inclusion Criteria
- Ages for both sexes fall between 30 and 70.
- Symptomatic OLP has been diagnosed clinically and verified histologically.
- Participants who sign a written consent form after being fully informed about the study.
Exclusion Criteria
- Treatment with a systemic or locally administered systemic medication within the previous three months before the commencement of the research.
- Patients now taking or who have just stopped taking an NSAIDs (both steroidal and non steroidal) for pain or inflammation.
- Patients who have been diagnosed with a malignant tumor or tumors.
- Women who are expecting or nursing.
- Inmates, the mentally ill, the elderly, etc, all fall into this category.
Data sourced from ClinicalTrials.gov (NCT06078579). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.